-

QuantHealth Secures Strategic Investment from Sanofi Ventures to Accelerate AI-Driven Clinical Trials

Sanofi and QuantHealth team up to advance AI-powered digital twins and clinical trial simulations to accelerate drug development

TEL AVIV, Isreal & CAMBRIDGE, Mass.--(BUSINESS WIRE)--QuantHealth, a pioneer in AI-driven clinical trial simulation, announced a strategic investment from Sanofi Ventures, the venture capital arm of global healthcare leader Sanofi. The investment will accelerate QuantHealth’s efforts to bring scalable, patient-level simulations and digital twin technologies to the forefront of drug development, bringing its total funds raised to $30 million.

QuantHealth’s platform enables pharmaceutical companies to virtually simulate clinical trials using real-world data and advanced AI models. By generating millions of patient-level digital twins, the platform predicts trial outcomes and optimizes protocol design, aiming to improve trial success rates, timelines, and cost efficiency.

The investment has further catalyzed an enterprise strategic relationship that supports Sanofi’s focus on integrating advanced AI and digital technologies to drive transformation across its R&D ecosystem. As part of the investment, Cris De Luca, Partner at Sanofi Ventures, will join as an observer on QuantHealth’s Board of Directors.

“We’re proud to welcome Sanofi Ventures as an investor and strategic ally in our journey,” said Orr Inbar, CEO and Co-founder of QuantHealth. “Sanofi is at the forefront of digital transformation in pharma, and this relationship will help us scale our impact and bring more predictive, AI-driven approaches to clinical development.”

“QuantHealth has the potential to transform how clinical trials are designed and optimized,” said Cris De Luca, Partner at Sanofi Ventures. “Their approach to leveraging digital twins and real-world data is advancing the next generation of R&D, and I look forward to supporting the team.”

“At Sanofi, we are building an AI-first organization, and engaging with innovators like QuantHealth is central to our strategy,” said Emmanuel Frenehard, Chief Digital Officer at Sanofi. “Their platform represents an important opportunity to reimagine clinical trial design through simulation, and we’re excited to explore this capability together.”

This investment and enterprise relationship underscores a shared commitment to advancing drug development through the responsible use of artificial intelligence in life sciences.

About QuantHealth

QuantHealth is an AI-driven clinical trial simulation company that helps pharmaceutical companies design faster, more successful trials using real-world data and predictive modeling. With access to over 350 million patient records and proprietary AI algorithms, QuantHealth’s platform simulates trials at scale to optimize protocols, reduce risk, and accelerate timelines.

About Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing globally in early-stage biotech and digital health companies aligned with Sanofi’s mission to chase the miracles of science. Areas of focus include immunology, oncology, rare diseases, vaccines, and digital innovation.

Contacts

Caroline Rueve
SolComms
QuantHealth@solcomms.co

QuantHealth


Release Versions

Contacts

Caroline Rueve
SolComms
QuantHealth@solcomms.co

More News From QuantHealth

QuantHealth Bolsters Executive Leadership Team to Support Its Expanding Product Portfolio and Growing Client Footprint

TEL AVIV, Israel--(BUSINESS WIRE)--QuantHealth, a pioneer in AI-driven clinical trial simulation, today announced the expansion of its executive leadership team with the appointments of Nadav Weinberg as Senior Vice President of Sales and Heather Adamson as Head of Marketing and Communications. The announcement comes as the company enters its next phase of commercial growth following rapid customer adoption and the recent launch of its real-time clinical trial simulation solution. As the SVP of...

QuantHealth Achieves Impressive 8x Financial Growth Across Life Sciences Engagements

TEL AVIV, Israel--(BUSINESS WIRE)--QuantHealth, a pioneer in AI-driven clinical trial simulations, today announced a record year of growth, with sales increasing 8x through new and expanding engagements across life sciences organizations. This industry-leading pace of adoption reinforces the value of AI-driven clinical trial prediction to accelerate and simplify the costly, complex journey of bringing new drugs to market, while also identifying opportunities to improve the commercial impact of...

QuantHealth Successfully Simulates 350+ Clinical Trials with 90% Accuracy, Delivering $31.4M in Savings for a Top-10 Pharma Company

TEL AVIV, Israel--(BUSINESS WIRE)--QuantHealth, the AI-powered clinical simulation company, today announced it has successfully simulated the results from over 350 clinical trials, achieving up to 90 percent predictive accuracy and delivering measurable impact across a range of development programs. The company’s technology is now being deployed across 23 therapeutic areas, including oncology, immunology, cardiometabolic diseases, and gastroenterology, enabling drug developers to optimize trial...
Back to Newsroom